Skip to content
MarketScale
‹ Back to IndustriesSciences

How Are AI Pros Weighing ChatGPT’s Role in the World of Science?

New evolving and fast-developing AIs have started rising to fame in recent years, and with the recent invention of ChatGPT – an AI chatbot launched in late 2022 which gained over 100 million users within the first two months of launching – people from all around the world are starting to question the role of AI technology…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By carey.scott · AiChat GptDeveloping AiScience
Share

Key takeaways

01

New evolving and fast-developing AIs have started rising to fame in recent years, and with the recent invention of ChatGPT – an AI chatbot launched in late 2022 which gained over 100 million users within the first two months of launching – people from all around the world are starting to question the role of AI technology…

New evolving and fast-developing AIs have started rising to fame in recent years, and with the recent invention of ChatGPT – an AI chatbot launched in late 2022 which gained over 100 million users within the first two months of launching – people from all around the world are starting to question the role of AI technology in their daily lives. Among these uncertainties is ChatGPT’s role in the world of science.

Will there be a huge impact of ChatGPT and developing AI in science? How will Chat GPT and developing AI contribute to modern science?

Biologists like Casey Greene and Milton Pividori see the tool as incredibly useful. After running their own research of using the tool for improving the quality and readability of academic manuscripts, Pividori concluded that ChatGPT, alongside other AI tools, is adding value to their lives by making helping scientists be “more productive as researchers.”

Meanwhile, other scientists are saying that they now regularly use LLMs (large language models like ChatGPT) not only to edit manuscripts but also to help them write or check code and to brainstorm ideas. As Nature.com reports, scientists like Almira Osmanovic Thunström, a neurobiologist at Sahlgrenska University Hospital in Gothenburg, says the use of ChatGPT will keep scientists from needing to “sit and write long introductions for grant applications.”

That being said, many scientists and researchers have pointed out a few disadvantages of AI tools. These are in the form of inaccurate information and fictitious citations presented by AI machines, giving scientists a reason to rely less on AI and more on their own manual research and cross-referencing. Can researchers confidently pinpoint ChatGPT’s role in the world of science?

Ganesh Gopalan, CEO and co-founder of Gnani.ai, a conversational AI platform with a focus on customer experience enhancement, weighs in on the impact of ChatGPT and other developing AI tools in the world of science and the difference it can make in research fields.

Ganesh Gopalan’s Thoughts

“ChatGPT is going to help researchers automate all their routine activities such as writing publications, reviewing documents are automatically creating extracts.

These articles typically warn of the pitfalls in terms of biases that ChatGPT could throw up and the possible inaccuracies. So, what I thought the best thing to evaluate this is to ask ChatGPT the same question. When I ask ChatGPT the same questions, I got a lot more results such as the influence on drug discovery, the influence on analyzing large pieces of scientific data and finding the relationships.

So essentially, I guess ChatGPT has a lot of benefits for science but you’ve gotta be a little careful on the biases and also on the accuracy of the data.”

Article written by Azam Saghir.

About the author

C
carey.scott

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

C
carey.scott